期刊文献+

磺脲类合并二甲双胍失效的2型糖尿病患者应用胰岛素治疗和联合治疗方案的临床观察 被引量:2

下载PDF
导出
摘要 目的 :探讨磺脲类合并二甲双胍失效的 2型糖尿病应用胰岛素治疗和联合治疗方案的疗效。方法 :将 49例磺脲类合并二甲双胍失效的 2型糖尿病患者随机分为胰岛素治疗组 (n =2 4)和联合组 (n =2 5 )。治疗 12周后 ,两组的血糖控制、胰岛素剂量、体重、接受胰岛素治疗的程度给予比较。结果 :两组的血糖均显示较好的控制(各自与治疗前相比 ,P <0 0 1) ,但联合组与胰岛素治疗组相比应用胰岛素剂量少 (P <0 0 1) ,体重增加较少 (P <0 0 1) ,接受胰岛素治疗的程度较好 (P <0 0 1)。结论 :对于口服降糖药继发失效的 2型糖尿病患者 ,早期应用联合治疗可能是一种较好的选择。
出处 《实用医学杂志》 CAS 2003年第7期736-737,共2页 The Journal of Practical Medicine
  • 相关文献

参考文献6

  • 1UKPDS Group. A 6-year randomized prospective controlled trail comparing sulfonylurea, insulin and metformin therapy in patients with newly diagnesed type 2 diabetes that could not be controlled with diet therapy.Ann Intern Med, 1998,128(2) : 165 ~ 175.
  • 2Ravnik-Oblak M, Mrevlje F. Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure. Diabetes Res Clin Pract,1995,30(1):27 ~ 35.
  • 3Rachman J, Levy JC, Barrow BA, et al. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy. Diabetes, 1997,46(10) : 1557 ~ 1562.
  • 4Trischitta V, Italia S, Raimondo M, et al. Efficacy of combined treatments in NIDDm patients with secondary failure to sulphonylureas.Is it pridectable? J Endocrinol Invest, 1998,21(11):744 ~ 777.
  • 5Chow CC, Tsang LW, Sorensen JP, et al. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care, 1995,18 ( 3 ) : 307 -314.
  • 6Clauson P, Karland S, Steen L, et al. Daytime glibenclamide and bedtime insulin compared to intensive insulin treatment in secondary sulphonylurea failure:a 1-year follow-up. Diabet Med, 1996,13(5) :471 ~ 477.

同被引文献18

  • 1王毅飞,伊娜,张松,徐谷根,林延德.胰岛素加用罗列酮治疗血糖控制不良的2型糖尿病患者疗效观察[J].中国实用内科杂志,2004,24(7):434-435. 被引量:5
  • 2United Kingdom Prospective Diabetes Study 24:a 6-year,randomized,controlled trail comparing sulfonylurea,insulin and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy[J].Ann Intern Med,1998,128(3):165-175.
  • 3SPIEGELMAN B M.PPAR-gamma:adipogenic regulator and thiazolidinedione receptor[J].Diabetes,1998,47(4):507-514.
  • 4YONG P W,CAWTHORNE M A,COYLE P J,et al.Repeat treatment of obese mice with BRL49653,a newlypotent insulin action in white adipocytes.Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling[J].Diabetes,1995,44(11):1087-1092.
  • 5JONES N P,MATHER R,OWEN S,et al.Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin[J].Diabetologia,2000,43 (Suppl 1):A192.
  • 6RASKIN P,RENDELL M,RIDDLE M C,et al.A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes[J].Diabetes Care,2001,24(7):1226-1232.
  • 7BUCH H N,BASKAR V,BARTON D M,et al.Combination of insulin and thiazolidinedione therapy in massively obese patients with type 2 diabetes[J].Diabet Med,2002,19(7):572 -574.
  • 8Matthews DR, Cull CA, Stratton IM, et al. Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group [J]. Diabet Med, 1998,15(4) :297-303.
  • 9中华医学会糖尿病学分会.中国2型糖尿病防治指南[S].2013:22-23.
  • 10Sigh S, Loke YK, Ferburg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis[J]. JAMA, 2007, 298(10) : 1189-1195.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部